These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

512 related articles for article (PubMed ID: 30198793)

  • 1. The development of efflux pump inhibitors to treat Gram-negative infections.
    Blanco P; Sanz-García F; Hernando-Amado S; Martínez JL; Alcalde-Rico M
    Expert Opin Drug Discov; 2018 Oct; 13(10):919-931. PubMed ID: 30198793
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efflux-mediated Multidrug Resistance in Critical Gram-negative Bacteria and Natural Efflux Pump Inhibitors.
    Nanjan P; Bose V
    Curr Drug Res Rev; 2024; 16(3):349-368. PubMed ID: 38288795
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Multidrug efflux pumps and their role in antibiotic and antiseptic resistance: a pharmacodynamic perspective.
    Alibert S; N'gompaza Diarra J; Hernandez J; Stutzmann A; Fouad M; Boyer G; Pagès JM
    Expert Opin Drug Metab Toxicol; 2017 Mar; 13(3):301-309. PubMed ID: 27764576
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Broad-specificity efflux pumps and their role in multidrug resistance of Gram-negative bacteria.
    Nikaido H; Pagès JM
    FEMS Microbiol Rev; 2012 Mar; 36(2):340-63. PubMed ID: 21707670
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An original deal for new molecule: reversal of efflux pump activity, a rational strategy to combat gram-negative resistant bacteria.
    Pagès JM; Amaral L; Fanning S
    Curr Med Chem; 2011; 18(19):2969-80. PubMed ID: 21651484
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Understanding efflux in Gram-negative bacteria: opportunities for drug discovery.
    Schweizer HP
    Expert Opin Drug Discov; 2012 Jul; 7(7):633-42. PubMed ID: 22607346
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical impact of the over-expression of efflux pump in nonfermentative Gram-negative bacilli, development of efflux pump inhibitors.
    Vila J; Martínez JL
    Curr Drug Targets; 2008 Sep; 9(9):797-807. PubMed ID: 18781925
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Practical applications and feasibility of efflux pump inhibitors in the clinic--a vision for applied use.
    Lomovskaya O; Bostian KA
    Biochem Pharmacol; 2006 Mar; 71(7):910-8. PubMed ID: 16427026
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Potential strategies for the eradication of multidrug-resistant Gram-negative bacterial infections.
    Huwaitat R; McCloskey AP; Gilmore BF; Laverty G
    Future Microbiol; 2016 Jul; 11():955-72. PubMed ID: 27357521
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efflux in Gram-negative bacteria: what are the latest opportunities for drug discovery?
    Gil-Gil T; Laborda P; Ochoa-Sánchez LE; Martínez JL; Hernando-Amado S
    Expert Opin Drug Discov; 2023 Jun; 18(6):671-686. PubMed ID: 37199662
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mechanistic Understanding Enables the Rational Design of Salicylanilide Combination Therapies for Gram-Negative Infections.
    Copp JN; Pletzer D; Brown AS; Van der Heijden J; Miton CM; Edgar RJ; Rich MH; Little RF; Williams EM; Hancock REW; Tokuriki N; Ackerley DF
    mBio; 2020 Sep; 11(5):. PubMed ID: 32934086
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Multidrug efflux pumps of Gram-positive bacteria.
    Schindler BD; Kaatz GW
    Drug Resist Updat; 2016 Jul; 27():1-13. PubMed ID: 27449594
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Multidrug Efflux Pumps and the Two-Faced Janus of Substrates and Inhibitors.
    Zgurskaya HI; Walker JK; Parks JM; Rybenkov VV
    Acc Chem Res; 2021 Feb; 54(4):930-939. PubMed ID: 33539084
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Novel β-lactam-β-lactamase inhibitor combinations: expectations for the treatment of carbapenem-resistant Gram-negative pathogens.
    Karaiskos I; Galani I; Souli M; Giamarellou H
    Expert Opin Drug Metab Toxicol; 2019 Feb; 15(2):133-149. PubMed ID: 30626244
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efflux Pump Inhibitors: A Novel Approach to Combat Efflux-Mediated Drug Resistance in Bacteria.
    Wang Y; Venter H; Ma S
    Curr Drug Targets; 2016; 17(6):702-19. PubMed ID: 26424403
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Curative Treatment of Severe Gram-Negative Bacterial Infections by a New Class of Antibiotics Targeting LpxC.
    Lemaître N; Liang X; Najeeb J; Lee CJ; Titecat M; Leteurtre E; Simonet M; Toone EJ; Zhou P; Sebbane F
    mBio; 2017 Jul; 8(4):. PubMed ID: 28743813
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mechanisms of antimicrobial resistance in
    Gil-Gil T; Martínez JL; Blanco P
    Expert Rev Anti Infect Ther; 2020 Apr; 18(4):335-347. PubMed ID: 32052662
    [No Abstract]   [Full Text] [Related]  

  • 18. Multidrug efflux pumps in Gram-negative bacteria and their role in antibiotic resistance.
    Blair JM; Richmond GE; Piddock LJ
    Future Microbiol; 2014; 9(10):1165-77. PubMed ID: 25405886
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Extending the Potency and Lifespan of Antibiotics: Inhibitors of Gram-Negative Bacterial Efflux Pumps.
    Duffey M; Jumde RP; da Costa RMA; Ropponen HK; Blasco B; Piddock LJV
    ACS Infect Dis; 2024 May; 10(5):1458-1482. PubMed ID: 38661541
    [TBL] [Abstract][Full Text] [Related]  

  • 20. What's new in the treatment of multidrug-resistant gram-negative infections?
    Mo Y; Lorenzo M; Farghaly S; Kaur K; Housman ST
    Diagn Microbiol Infect Dis; 2019 Feb; 93(2):171-181. PubMed ID: 30224228
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.